Adriamycin (ADR) induces the over-expression of P-glycoprotein (P-gp) and multiple drug resistance in breast cancer cells. However, the biochemical process and underlying mechanisms are not clear. Our previous study revealed that ADR increased reactive oxygen species (ROS) generation and decreased glutathione (GSH) biosynthesis, while N-acetylcysteine, the ROS scavenger, reversed the over-expression of P-gp. The present study showed that ADR inhibited the influx of cystine (the source material of GSH) and the activity of the SLC7A11 transporter (in charge of cystine uptake) in MCF-7 cells. For the first time, we showed that the down-regulation/silence of SLC7A11, or cystine deprivation, or enhanced ROS exposure significantly increased P-gp expression in MCF-7 cells. The down-regulation of SLC7A11 markedly enhanced ROS induced P-gp over-expression and drug resistance in MCF-7 cells; a combination of either an inhibited/silenced SLC7A11 or cystine deprivation and increased ROS dramatically promoted P-gp expression, which could be reversed by N-acetylcysteine. In contrast, the over-expression of SLC7A11, or supplementation with sufficiently cystine, or treatment with N-acetylcysteine significantly decreased P-gp expression and activity. It was suggested that ROS and SLC7A11/cystine were the two relevant factors responsible for the expression and function of P-gp, and that SLC7A11 might be a potential target modulating ADR resistance.
Chemotherapy is one of the most effective treatments in current breast cancer therapy. Since the introduction of chemotherapy and earlier diagnoses in the middle 1990s, breast cancer-induced morbidity and mortality have been significantly reduced, and the lifespan of breast cancer patients has been prolonged 1 . However, the development of drug resistance eventually becomes a great challenge to the successful chemotherapy of breast cancer. It is estimated that a significant number of breast cancer patients (up to 50%) are not responsive to current chemotherapeutic regimens 2 . Resistance to a single antitumour drug tends to trigger the development of pleiotropic resistance to a wide variety of structurally and functionally independent anticancer agents, and this phenomenon is called multidrug resistance (MDR). It has been established that membrane proteins, such as the multidrug resistance protein (MRP) and the breast cancer resistance protein (BCRP) of the ATP binding cassette (ABC) transporter family that encodes efflux pumps, play key roles in the development of the multidrug resistance phenotype. The over expression of these transporters has frequently been observed in many types of human malignancies that respond poorly to chemotherapeutic agents.
As a frontline anti-tumour drug, Adriamycin (ADR) is a DNA intercalating agent and one of the most active agents against breast cancer 3, 4 . Unfortunately, like many other chemotherapeutic agents, the continuous administration of ADR causes drug resistance so that the therapeutic efficacy dramatically declines 5 . Clinical data have confirmed that both chemotherapy sensitivity and patient survival were negatively correlated with P-glycoprotein (P-gp) expression. Current evidence has suggested that ADR resistance is deeply involved in the induction of highly expressed P-gp, which, in turn, enhances the efflux of ADR from inside cells 6 . Additionally, the breast cancer cell line MCF-7 can be induced by fairly low exposure to ADR in vitro to become the stable ADR-resistance cell line MCF-7R, with the distinct biological characteristic of hundreds of times higher P-gp expression. To date, it remains elusive which factor plays a crucial role in initiating the over-expression of P-gp, although genomic and proteomic studies have suggested that potential factors such as cyclin, apoptin, microRNA-451, and Anxa2 are involved at the transcriptional and posttranscriptional levels [7] [8] [9] [10] [11] [12] [13] [14] .
Recently, accumulated evidence has demonstrated that, when cells are treated with antitumour drugs, redox signals are activated and affect processes such as apoptosis, metastasis, and the inflammatory response, leading to attenuated efficacy. It was generally accepted that redox signals modulate the transporters of membrane proteins via mechanisms that include (a) conformational changes of the transporters, (b) regulation of the biosynthesis cofactors required for the transporter's function, (c) regulation of the expression of transporters at the transcriptional, posttranscriptional, and epigenetic levels, and (d) amplification of the copy number of the genes encoding these transporters. However, genetic and proteomic studies did not identify the direct factors contributing to the generation and homeostasis of reactive oxygen species (ROS), and conflicting opinions emerged regarding the relationship and mechanism between redox signaling and multidrug resistance in cancer cells [15] [16] [17] [18] [19] . Our previous study of metabolomics revealed that ADR switched metabolic pathways in MCF-7S cells, and the ADR-resistant cell line MCF-7R appeared to demonstrate a distinctly altered metabolic pattern from that of the sensitive cell line MCF-7S. For example, we found that ADR promoted notable metabolism reprogramming, including markedly disturbed biosynthesis of proteins, purines, pyrimidines, glutathione and glycolysis, whilst enhancing the glycerol metabolism of MCF-7S cells 20 . The elevated glycerol metabolism and down-regulated glutathione biosynthesis suggested an increased ROS generation and a weakened ability to balance ROS, respectively. Oxidative stress and elevated ROS usually enhance the production of reduced glutathione (GSH) via the up-regulation of the expression of γ-glutamylcysteine synthetase (γ-GCS), the rate limiting enzyme for the biosynthesis of GSH 21 . Therefore, the obvious contradiction between the increased ROS and decreased GSH induced by ADR greatly raised our interest in the underlying mechanism contributing to the up-regulation of P-gp.
Thus, the present study was designed to clarify the effect of ADR on the generation and homeostasis of ROS (e.g., the synthesis of GSH), and redox regulation of P-gp over-expression induced by ADR. As a crucially important node of the cellular antioxidant system, SLC7A11 encodes for a subunit of the xCT cystine/glutamate amino acid bilateral transport system, and cystine represents the synthesis of GSH [22] [23] [24] . Based on our previous results 20 , we fully investigated the role of SLC7A11 and cystine in the over-expression of P-gp in the current study. Moreover, to exclude the possible direct activity of ADR on P-gp, the effect of the direct addition of ROS agents and the direct modulation on SLC7A11 or cystine, alone or in combination, were evaluated, although a potential correlation between ROS and P-gp has been reported [25] [26] [27] . Our goal was to examine the specific role of elevated ROS coupled with a decreased anti-oxidative capacity in the ADR-induced over-expression of P-gp.
Results
The differential impact of ADR on GSH/GSSG ratio, the influx of cystine and the expression of SLC7A11 in MCF-7S and MCF-7R cells. It was previously shown that ADR promoted the generation of ROS in MCF-7S cells 20 . In additon, ADR significantly increased P-gp expression dose-dependently and time-dependently, while the ROS scavenger N-acetylcysteine (NAC) exhibited a distinct antagonistic effect, suggesting that ADR resistance was involved in aggravated oxidative stress 20 . In the present study, we found that the level of ROS in ADR-induced MCF-7R cells was approximately 4 times that in MCF-7S cells (Fig. 1A) , and the baseline GSH (reduced glutathione)/GSSG (oxidized glutathione) ratio of MCF-7R cells was lower than that of MCF-7S cells, indicating a poor capacity for the removal of ROS 28, 29 , in concordance with previous results (Fig. 1B ). In addition, ADR treatment decreased the intracellular GSH/GSSG value in MCF-7S cells, which was significantly reversed by NAC ( Fig. 1B) .
To monitor cystine (the source material for the synthesis of GSH) uptake, extracellular cystine of both MCF-7S and MCF-7R cells was detected by GC/MS, with the same initial concentration of cystine (1.0 mM) in the culture medium. We observed that extracellular cystine was much higher in MCF-7R cells than in MCF-7S cells over time, suggesting a much faster influx/utilization of cystine in MCF-7S cells than in MCF-7R cells (Fig. 1C ). In fact, SLC7A11 controls not only the uptake of cystine but also the efflux of glutamic acid [22] [23] [24] . Our data showed that ADR intervention reduced the influx of cystine into cells, and slightly reduced the efflux of glutamate out of cells so that more cystine and less glutamate were present in the culture medium ( Fig. 1D ), indicating that ADR significantly inhibited the function of SLC7A11. Further examination of SLC7A11 at the mRNA level revealed that its expression in MCF-7S cells was approximately 5 times that in MCF-7R cells, the ADR-induced cell line ( Fig. 1E ). Moreover, a significant inhibition of SLC7A11 was observed in MCF-7S cells after exposure to ADR ( Fig. 1E and F). For MCF-7R cells, a longer exposure at higher levels also significantly inhibited SLC7A11 ( Fig. 1G ), although MCF-7R cells did not respond to ADR at the same level as for MCF-7S cells. Together with our previous data 20 , the above results revealed that, in addition to P-gp over-expression, ADR increased ROS production and inhibited SLC7A11 function and cystine uptake, suggesting an attenuated capacity for anti-oxidative stress with a decreased GSH/GSSG ratio.
Effects of ROS agents on P-gp expression in MCF-7S cells. The level of ROS in MCF-7R cells, a stable
cell line induced by continuous induction of ADR, has been shown to be approximately 4 times that in MCF-7S cells (Fig. 1A) . Moreover, ADR significantly elevated the ROS level and P-gp expression, which could be reversed by NAC 20 , suggesting a distinct correlation between the intracellular ROS level and P-gp over-expression. To exclude other potentially latent factors involved in P-gp over-expression and to explore the direct correlation between ROS and P-gp, MCF-7S cells were exposed to two typical ROS agents. It was confirmed that the ROS agents, H 2 O 2 and ROSup dose-dependently produced a large amount of ROS ( Supplementary Fig. S1 ). Thus, we found that as the ROS production increased, the mRNA expression of P-gp was higher, which could be efficiently reversed by NAC, indicating a direct effect of ROS on the elevation of P-gp ( Fig. 2A and B ). Consistent results were also achieved by immunofluorescence analysis, with flow cytometry (Fig. 2C ) and laser confocal scanning ( Fig. 2D ). Nevertheless, the highest level of ROSup greatly promoted the expression of P-gp as much as 19.6 fold ( Fig. 2B1 ), indicating that an extensive or sustained exposure and excessive ROS remarkably enhanced P-gp expression. These results strongly suggested that ROS was an initial factor contributing to the over-expression of P-gp.
Modulatory effects of SLC7A11 on P-gp expression and function. It is well known that, SLC7A11
serves as the major means of increasing intracellular cysteine and accelerating the production of GSH [22] [23] [24] . It was shown that SLC7A11 expression in MCF-7R cells was much lower than that in MCF-7S cells, and ADR inhibited SLC7A11 expression in MCF-7S and MCF-7R cells ( Fig. 1E -G). We further examined the regulatory effect of SLC7A11 on the expression and function of P-gp with siRNA ( Fig. 3A ). We found that when the SLC7A11 expression level was decreased by 25%, 34%, 46% via siRNA silencing, in response, P-gp mRNA expression was increased by 1.34, 3.19, and 4.20 times, respectively, compared with controls ( Fig. 3B1 ). Additionally, there was a negative correlation between the mRNA level of SLC7A11 and P-gp ( Fig. 3B2 ). It was also shown that the down-regulation of SLC7A11 enhanced P-gp protein expression, which was confirmed by immunofluorescence analysis with flow cytometry ( Fig. 3C ) and laser confocal scanning ( Fig. 3E ). Moreover, fluorescence microscopy analysis of intracellular Rhodamine 123 (Rho 123, the fluorescent substrate of P-gp) showed that the function of P-gp was enhanced after SLC7A11 was silenced, indicated by the increased efflux of Rho 123 (Fig. 3F ). The up-regulation of ROS and P-gp induced by SLC7A11 silencing could be reversed by treatment with the ROS scavenger NAC ( Fig. 3D-F ). In addition, an SLC7A11 inhibitor, sulfasalazine 30, 31 increased intracellular ROS production and P-gp expression ( Fig. 3G ). These findings suggested that ROS was the key intermediate factor in the regulation of P-gp expression by SLC7A11.
By means of SLC7A11 plasmid transfection into MCF-7S and MCF-7R cells, we established two cell lines that stably and highly expressed SLC7A11 which was validated at the gene, protein and function levels ( Supplementary  Fig. S2 ). As SLC7A11 function strengthened, more extracellular cystine was taken up and more intracellular glutamate was excreted ( Supplementary Fig. S2C and D) , indicating the successful construction of cell lines that expressed high levels of SLC7A11. The over-expression of SLC7A11 led to significantly lower ROS levels and P-gp expression in both MCF-7S and MCF-7R cells ( Fig. 4A and B ), in concordance with the decreased function of P-gp, which was indicated by the increased accumulation of intracellular Rho123 (Fig. 4E ). Interestingly, ADR induced a much higher fold change in P-gp expression in SLC7A11 over-expressed MCF-7S cells (Fig. 4B1 ), indicating that MCF-7S cells over-expressed SLC7A11 became more sensitive to ADR. In addition, ADR appeared to be more toxic to MCF-7 cells with SLC7A11 over-expression ( Fig. 4C) . Treatment with the ROS agent, H 2 O 2 These data strongly suggested that the down-regulation of SLC7A11 was the crucially important factor that contributed to the over-expression of P-gp, mediated by the ROS level.
Deprivation and sufficient supplementation of cystine positively or negatively affected P-gp expression in MCF-7S and MCF-7R cells, respectively.
Cystine is known to be taken up through SLC7A11 and is utilized as the source material for the synthesis of antioxidant GSH [22] [23] [24] . We have shown that cystine in the culture medium is depleted more quickly in MCF-7S cells than in MCF-7R cells (Fig. 1C) , and ADR decreased the influx of cystine ( Fig. 1D ), suggesting that cystine was involved in ADR-induced resistance. To examine the effect of cystine on ROS and P-gp levels, cystine was added or removed. Supplementary cystine significantly decreased ROS levels and P-gp expression in MCF-7S and MCF-7R cells ( Fig. 5A and B) . Consistent results were confirmed by flow cytometry (Fig. 5C ), Western blot ( Fig. 5D ), laser confocal scanning microscopy ( Fig. 5E ) and intracellular Rho 123 analysis ( Fig. 5F ) in MCF-7S cells. In addition, we also found that the high levels of ROS and P-gp induced by cystine deprivation could be reversed by the ROS scavenger NAC (Fig. 5A ,E and F). However, it take a longer time in MCF-7R cells ( Fig. 5B and D) , partly due to a slower uptake of cystine in MCF-7R cells (low expression of SLC7A11). Moreover, cystine supplementation could reverse the elevation of ROS and P-gp induced by low-dose (0.2 μM) ADR intervention (Fig. 5G) , and could enhance the antitumour efficacy of ADR on MCF-7S cells (Fig. 5H) . The above data suggested that cystine depletion was another factor that modulated the expression of P-gp, which primarily depended on the intracellular ROS level.
Multiple factors of ROS generation, modulation of SLC7A11 and supplementary cystine involved in the expression and function of P-gp in MCF-7S cells. Our data demonstrated
that the single factor of either increased ROS or inhibited SLC7A11/cystine deprivation contributed to P-gp over-expression (Figs 2-5 ). Therefore, we investigated the effect of the combined factors on P-gp expression and function. The results revealed that the addition of 0.5 mM H 2 O 2 or the silencing of SLC7A11 increased P-gp expression by approximately 2-fold, which was much lower than the combination of the two factors (Fig. 6A ). Fluorescence quantitation of flow cytometry and Rho123 accumulation analysis clearly showed a much higher expression and function of P-gp induced by the combination of H 2 O 2 addition and the silencing of SLC7A11 ( Fig. 6B and C) . Moreover, the combination of cystine deprivation and the addition of H 2 O 2 dramatically reduced intracellular Rho123, indicating a much stronger activity of P-gp (Fig. 6E ). In addition, a weakened cytotoxicity of ADR was observed with the combination of increased ROS and inhibited SLC7A11/cystine deprivation ( Fig. 6D and F), in accordance with the significant up-regulation of P-gp. These data strongly indicated that the combination of ROS production and SLC7A11 modulation played a key role in the over-expression of P-gp. 
Discussion
Although it is commonly recognized that redox signals modulate the transporters of membrane proteins at genetic and proteomic levels 7-14 , the underlying mechanism that contributes to P-gp over-expression remain unclear. Current evidence has shown that the environmental scavenging of ROS (NAC) and the modulation of endogenous GSH synthesis affected the expression and function of P-gp similarly 32, 33 . In our present research, the combinational effects of ROS addition and the partial silencing of SLC7A11 greatly promoted the expression and activity of P-gp in MCF-7 cells (Fig. 6 ). By contrast, the single factor of either added ROS or down-regulated SLC7A11/inhibited influx of cystine only increased P-gp expression several times. Interestingly, NAC could also reverse the up-regulation of P-gp induced by SLC7A11 or cystine (Figs 3-5 ). Indeed, our findings strongly indicated that ROS and SLC7A11 were two related factors responsible for the expression and function of P-gp, and the combinational effect of increased ROS production and reduced ability of ROS scavenging (i.e., inhibition of SLC7A11 and reduced GSH synthesis) played a key role in the over-expression of P-gp induced by ADR. Recently, X Tang et al. reported that cystine deprivation triggered necrosis in triple-negative breast cancer (TNBC) cells 34 , and Feng Wang et al. found that ADR increased the expression of SLC7A11 in TNBC, while the inhibition of the SLC7A11 antiporter system sensitized TNBC cells to ADR 35 . These results indicated that SLC7A11 was a potential target for the enhancement of the anticancer efficacy of conventional therapy in patients with TNBC. However, our study clearly showed that ADR inhibited cystine influx, down-regulated SLC7A11 transporter activity in MCF-7 cells, and efficiently increased P-gp expression and function. The differential effects of ADR were probably dependent on the diverse subtypes of breast cancer cells, i.e., MCF-7 cells are luminal-type cells, while TNBC cells are basal-type cells 34 .
Actually, the mechanism of multidrug resistance is primarily involved in the up-regulation of multiple resistant transporters and has been well documented at the transcriptional and posttranscriptional levels. Mechanistic studies have suggested that redox signals modulate the transporters of membrane proteins [36] [37] [38] . However, the underlying biochemical process remains largely unclear regarding how ADR perturbs redox homeostasis and the identity of the crucial factor that dominates the increased expression of P-gp. To explore the underlying mechanism that contributes to the over-expression of P-gp, it was necessary to conduct a series of analyses on MCF-7S cells. In addition, data from MCF-7R cells (with hundreds of times more P-gp expression) could provide more information to confirm the mechanism that was found in MCF-7S cells. For example, our previous and present study revealed that there was a significant difference between MCF-7S and MCF-7R cells in terms of metabolic pattern 20 , intracellular ROS level, intracellular GSH/GSSG ratio, SLC7A11 expression and cystine uptake (Fig. 1) . Thus, we believed that these differences were involved in multiple resistance. What's more, data from MCF-7R cells assisted in providing strategies in modulating or reversing the over-expression of P-gp. For example, we observed that supplementary cystine could reduce the expression and function of P-gp, indicating its potential clinical value. However, to the best of our knowledge, no previous reports demonstrated a link between the SLC7A11/cystine metabolic pathway and the regulation of the efflux transporter P-gp. For the first time, we confirmed that the combination of elevated ROS and the inhibition of SLC7A11/cystine was the underlying mechanism that contributed to the over-expression of P-gp induced by ADR (Fig. 7) . Furthermore, the SLC7A11 transporter may be a potential target to modulate resistance.
Methods

Cell lines and culture. Human breast cancer MCF-7 cells and the ADR-resistant MCF-7 subline (MCF-7R)
were obtained from the Institute of Hematology and Blood Diseases Hospital (Tianjin, China). These cell lines were grown in RPMI-1640 medium supplemented with 10% (v/v) foetal bovine serum, 100 U/mL penicillin and 0.1 mg/mL streptomycin (Invitrogen, Carlsbad, CA, USA) at 37 °C in a 5% CO2 incubator.
Intracellular cystine and glutamic acid measurement. Cystine and glutamic acid were identified by metabolomic analysis as reported previously 20 and were compared with their respective reference standards. A relative quantitative measurement of intensity was achieved by calculating the area under the curve (AUC) of each peak, with a quant mass of m/z 348 and a retention time of 9.46 min for glutamic acid, and a quant mass of m/z 411 and a retention time of 12.99 min for cystine. Intracellular glutathione and ROS Measurement. MCF-7S and MCF-7R cells were cultured in 12-well plates. After treatment, the cells were harvested, and then the total glutathione (GSH and GSSG) was measured 
Reverse transcription PCR. Total RNA was isolated from MCF-7S and MCF-7R cells via the
TRIzol method 40 in accordance with the manufacturer's instructions and was quantified with ultraviolet spectrophotometry. Complementary DNA was synthesized with the PrimeScript RT Reagent Kit Perfect Real Time (Takara Biomedicals). The following primer sets were used in this study: human P-gp, 5′-GCTGGGAAGATCGCTACTGA-3′ and 5′-GGTACCTGCAAACTCTGA-3′; human SLC7A11, 5′-GCTGGGCTGAT T TATCT TCG-3′ and 5′-GAAAGCTGGGATGAACAGT-3′; human Actin 5′-GCGTGACATTAAGGAGAAG-3′ and 5′-GGGAAGGAAGGCTGG AAGA-3′. The reverse transcription reaction conditions were as follows: 37 °C for 15 min followed by 85 °C for 5 s. PCR was conducted using SYBR Premix Ex TaqTM II (Takara Biomedicals) according to the manufacturer's instructions. The PCR conditions were as follows: 95 °C for 15 s followed by 72 °C for 30 s and 60 °C for 60 s (40 cycles). All of the samples were quantified using the comparative Ct method for the relative quantification of gene expression, normalized to actin.
Western blotting analysis. Proteins (40 μg) in the membrane extracts or in the whole cell lysate were separated by 10% sodium dodecyl sulphate-polyacrylamide gel (SDS-PAGE) and transferred to polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA, USA). After blocking with 5% non-fat milk, the membrane was incubated with the primary antibodies against SLC7A11 (1:400, ab60171, Abcam, USA), P-gp (1:1000, ab170904, Abcam, USA), ATPase Na + /K + (1:10000, ab185210, Abcam, USA) overnight at 4 °C, followed by incubation with the appropriate horseradish peroxidase (HRP)-linked secondary antibodies for 1 h at 37 °C. The signals were detected with an enhanced chemiluminescence kit (Thermo Fisher Scientific, Waltham, MA, USA) and were captured with a ChemiDoc XRS + System (Bio-Rad, Hercules, CA, USA). The intensity of bands was quantified by Image Lab statistical software (Bio-Rad Laboratories, Hercules, CA, USA).
Intracellular accumulation of Rhodamine 123 (Rho 123) Assay.
The intracellular fluorescence intensity of Rho 123, a classic fluorescence substrate of P-gp, was monitored for the evaluation of P-gp function 41 . Thus, a high degree of intracellular fluorescence of Rho 123 represents the poor efflux function of P-gp. Briefly, MCF-7 cells were plated in 24-well plates and then were incubated with Hank's Balanced Salt Solution (HBSS; 37 °C, pH 7.4) containing Rho123 (5 μM) for 2 h. The accumulation was stopped by rinsing the cells with ice-cold HBSS. The cells were lysed, and the protein concentrations were measured via the Bradford method using the BCA protein assay kit (Beyotime, Jiangsu, China). In a parallel experiment, the intracellular accumulation of Rho123 was detected by fluorescence microscopy, or with a microplate reader Powerwave 200 (Bio-Tek Instruments, Winooski, VT, USA) with the excitation wavelength set at 485 nm and the emission wavelength set at 546 nm. Fluorescence values of Rho 123 were also normalized to the protein levels in each sample.
Cytotoxicity assay (MTT assay). MCF-7 cell viability was evaluated using the 3-(4,5-dime thythiazole-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. Cells were seeded into a 96-well plate (5 × 10 3 cells/well). Following the treatment, the cells were incubated with 20 µL (5 mg/mL) MTT for 4 hours at 37 °C. The medium was removed and the formazan crystals produced by viable cells were dissolved in 150 µL DMSO for 10 min at 37 °C. The absorbance was detected using a microplate reader Powerwave 200 (Bio-Tek Instruments, Winooski, VT, USA) at a wavelength of 570/695 nm.
Immunofluorescence assay of P-gp expression. MCF-7 cells were plated in 6-well plates before harvesting. After treatment and washing, the cells were fixed with 4% paraformal-dehyde solution, followed by washing and blocking. Next, the cells were incubated with the FITC-conjugated anti-P-gp polyclonal antibody or an isotype-matched negative control for 1 h at 37 °C (BD Biosciences, Franklin Lakes, NJ, USA). After washing, the cells were analysed via flow cytometry and the data were acquired on a BD FACSVerse (FACSCalibur, BD, Franklin Lakes, NJ, USA) and then were analysed with CELLQUEST software. MCF-7 cells were plated in Cell Imaging Coverglass (Eppendorf, USA), after treatment and washing, incubated with the FITC-conjugated 
